New AI Tool Pinpoints Genes and Drug Combinations That Restore Health in Diseased Cells

Key Takeaways: 

• Harvard researchers have developed PDGrapher, an AI tool that identifies genes and drug combinations most likely to restore diseased cells to a healthy state.
• The model uses graph neural networks to map cellular relationships and predict effective single or combined drug targets, significantly reducing the need for exhaustive drug screening.
• PDGrapher demonstrated high accuracy and speed across multiple cancer datasets, offering promise for personalised medicine and drug discovery in complex diseases such as cancer, Parkinson’s, and Alzheimer’s.
  
  

Introduction: A new era in drug discovery

Researchers at Harvard Medical School (HMS) have unveiled a powerful artificial intelligence (AI) model capable of identifying therapies that can reverse disease at the cellular level. This innovation, published in Nature Biomedical Engineering on 9 September, could reshape how new drugs are discovered, designed, and personalised for patients.

Unlike traditional approaches that examine one protein target or drug candidate at a time, this new model — named PDGrapher and freely available to researchers — analyses multiple cellular drivers of disease. It identifies the genes most likely to return diseased cells to normal function and pinpoints the most promising single or combined drug targets to correct the underlying cellular dysfunction.

“Traditional drug discovery resembles tasting hundreds of prepared dishes to find one that happens to taste perfect,” explained senior study author Marinka Zitnik, Associate Professor of Biomedical Informatics at HMS’s Blavatnik Institute. “PDGrapher works like a master chef who understands what they want the dish to be and exactly how to combine ingredients to achieve the desired flavour.”

Limitations of traditional drug discovery

Historically, drug discovery has focused on activating or inhibiting a single protein target. This approach has produced successful therapies such as kinase inhibitors, which block proteins that drive cancer cell growth. However, Zitnik emphasised that such strategies often fall short for diseases driven by multiple interacting pathways and genes.

She noted that many recent therapeutic breakthroughs — including immune checkpoint inhibitors and CAR T-cell therapies — work by targeting broader disease processes rather than single molecules. PDGrapher aims to expand this concept by identifying drug targets that can reverse signs of disease, even when the precise molecular mechanisms are not yet fully understood.

How PDGrapher works: Mapping complex cellular networks

PDGrapher is based on a graph neural network — a form of AI that analyses not only individual data points but also the relationships and interactions between them. In biological research, this means mapping how genes, proteins, and signalling pathways influence one another inside a cell.

Instead of screening thousands of compounds blindly, PDGrapher simulates what would happen if certain genes or pathways were switched off, dialled down, or targeted with a drug. It then predicts whether these interventions would shift a diseased cell towards a healthier state.

“Instead of testing every possible recipe, PDGrapher asks: ‘Which mix of ingredients will turn this bland or overly salty dish into a perfectly balanced meal?’” said Zitnik.

Testing and validation: Proving its predictive power

To train the model, researchers fed PDGrapher a dataset of diseased cells both before and after treatment, allowing it to learn which gene changes led to recovery.

They then evaluated the tool using 19 independent datasets across 11 cancer types, combining both genetic and drug-based experiments. PDGrapher was asked to propose treatment options for samples and cancer types it had never seen before.

The model accurately predicted known drug targets that had been deliberately excluded during training and identified new candidates supported by emerging evidence. Notably, it highlighted KDR (VEGFR2) as a target for non-small cell lung cancer, consistent with clinical findings, and identified TOP2A, an enzyme already targeted by chemotherapy, as a promising target for preventing metastasis in certain tumours.

PDGrapher consistently outperformed comparable AI models — ranking correct therapeutic targets up to 35 percent higher and producing results up to 25 times faster.

Implications for future drug discovery

By focusing on targets that directly reverse disease traits, PDGrapher streamlines the drug discovery process. This allows researchers to prioritise fewer, more promising interventions and to design experiments that are faster and more cost-effective.

This capability is particularly valuable for complex diseases such as cancer, where tumours often evade therapies that strike only one target. Because PDGrapher identifies multiple disease drivers, it offers a way to design combination treatments that could prevent drug resistance.

In the future, with further validation, PDGrapher could be applied to individual patients’ cellular profiles to create personalised treatment strategies.

Broader applications and ongoing research

Beyond cancer, the research team is using PDGrapher to investigate neurological conditions such as Parkinson’s disease and Alzheimer’s disease, aiming to identify genetic drivers that could restore neuronal health.

They are also collaborating with Massachusetts General Hospital’s Center for X-linked Dystonia-Parkinsonism (XDP) to map potential drug targets for this rare, inherited neurodegenerative disorder.

“Our ultimate goal is to create a clear road map of possible ways to reverse disease at the cellular level,” Zitnik stated.